• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    2/5/24 12:31:04 PM ET
    $ADVM
    $AKAN
    $ASLN
    $DMK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ADVM alert in real time by email

    Gainers

    • 4D Molecular Therapeutics (NASDAQ:FDMT) stock increased by 75.2% to $30.64 during Monday's regular session. The company's market cap stands at $1.3 billion.
    • Yield10 Bioscience (NASDAQ:YTEN) stock rose 61.76% to $0.37. The market value of their outstanding shares is at $4.4 million.
    • MorphoSys (NASDAQ:MOR) stock moved upwards by 50.76% to $16.69. The market value of their outstanding shares is at $2.5 billion.
    • Karyopharm Therapeutics (NASDAQ:KPTI) shares moved upwards by 31.73% to $1.37. The company's market cap stands at $156.9 million.
    • Adverum Biotechnologies (NASDAQ:ADVM) stock moved upwards by 28.86% to $1.83. The company's market cap stands at $184.8 million.
    • Mira Pharmaceuticals (NASDAQ:MIRA) shares moved upwards by 21.49% to $1.13. The company's market cap stands at $16.7 million.

    Losers

    • NanoString Technologies (NASDAQ:NSTG) stock declined by 70.9% to $0.14 during Monday's regular session. The company's market cap stands at $6.5 million.
    • Invitae (NYSE:NVTA) stock decreased by 61.9% to $0.15. The market value of their outstanding shares is at $42.5 million.
    • DMK Pharmaceuticals (NASDAQ:DMK) shares fell 52.5% to $0.25. The company's market cap stands at $2.4 million.
    • Intelligent Bio Solutions (NASDAQ:INBS) shares fell 37.82% to $3.7. The company's market cap stands at $2.6 million.
    • Akanda (NASDAQ:AKAN) stock declined by 18.18% to $0.32. The company's market cap stands at $1.8 million.
    • ASLAN Pharma (NASDAQ:ASLN) shares declined by 18.11% to $0.47. The market value of their outstanding shares is at $7.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADVM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADVM
    $AKAN
    $ASLN
    $DMK

    CompanyDatePrice TargetRatingAnalyst
    Karyopharm Therapeutics Inc.
    $KPTI
    3/10/2026$28.00Buy
    Rodman & Renshaw
    Karyopharm Therapeutics Inc.
    $KPTI
    2/5/2026Overweight
    Cantor Fitzgerald
    4D Molecular Therapeutics Inc.
    $FDMT
    1/28/2026$33.00Overweight
    Barclays
    Adverum Biotechnologies Inc.
    $ADVM
    11/17/2025Buy → Neutral
    H.C. Wainwright
    4D Molecular Therapeutics Inc.
    $FDMT
    11/7/2025Underweight → Equal-Weight
    Morgan Stanley
    Karyopharm Therapeutics Inc.
    $KPTI
    10/13/2025$15.00Neutral → Buy
    H.C. Wainwright
    Karyopharm Therapeutics Inc.
    $KPTI
    7/16/2025Buy → Neutral
    H.C. Wainwright
    Karyopharm Therapeutics Inc.
    $KPTI
    7/11/2025$27.00Buy
    H.C. Wainwright
    More analyst ratings

    $ADVM
    $AKAN
    $ASLN
    $DMK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Karyopharm Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $28.00

    3/10/26 8:41:07 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics

    Cantor Fitzgerald initiated coverage of Karyopharm Therapeutics with a rating of Overweight

    2/5/26 6:58:02 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on 4D Molecular Therapeutics with a new price target

    Barclays resumed coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $33.00

    1/28/26 7:14:57 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    $AKAN
    $ASLN
    $DMK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Commercial Officer Cheng Sohanya Roshan sold $43,321 worth of shares (4,604 units at $9.41), decreasing direct ownership by 4% to 107,317 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    3/3/26 4:27:11 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CLO&Secretary Mano Michael sold $33,178 worth of shares (3,526 units at $9.41), decreasing direct ownership by 4% to 93,964 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    3/3/26 4:28:39 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Medical Officer Rangwala Reshma sold $47,669 worth of shares (5,066 units at $9.41), decreasing direct ownership by 8% to 56,739 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    3/3/26 4:25:50 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADVM
    $AKAN
    $ASLN
    $DMK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    CEO, PRESIDENT AND DIRECTOR Fischer Laurent bought $553,917 worth of shares (128,699 units at $4.30), increasing direct ownership by 177% to 201,513 units (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/8/25 9:45:06 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF OPERATING OFFICER Soparkar Peter bought $211,000 worth of shares (50,000 units at $4.22), increasing direct ownership by 166% to 80,189 units (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/8/25 9:45:04 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    $AKAN
    $ASLN
    $DMK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEWTON, Mass., March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,450 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of February 28, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three co

    3/2/26 4:05:00 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    First Towers & Fiber Corp. Owns the Largest Dark Fiber Network in Central Mexico

    Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, announced today plans to further expand the leasing of its approximately 700-kilometre dark fiber optic network located in Central Mexico. The network represents the largest dark fiber infrastructure in the region, serving several of Mexico's most active industrial corridors and fastest-growing state economies.The network was constructed following the execution of a 20-year long-term dark fiber lease agreement with Telefónica, the Spanish multinationa

    2/27/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry

    Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver annual production cost savings of more than 40% with expected improvement of approximately 20 percentage points in gross margin annually Doubled in-house lateral flow test strip production capacity strengthens vertical integration, accelerates R&D, and enables panel expansion NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today a

    2/25/26 8:45:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ADVM
    $AKAN
    $ASLN
    $DMK
    SEC Filings

    View All

    MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)

    3/3/26 4:01:24 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    2/27/26 3:57:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/25/26 9:15:25 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ADVM
    $AKAN
    $ASLN
    $DMK
    Leadership Updates

    Live Leadership Updates

    View All

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    4DMT Appoints Kristian Humer as Chief Financial Officer

    EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company's financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives. Mr. Humer is an accomplished finance executive and biotechnology leader with more than two decades of experience

    11/17/25 6:00:00 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ADVM
    $AKAN
    $ASLN
    $DMK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

    SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

    11/15/24 5:05:27 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

    SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

    11/14/24 6:57:12 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    $AKAN
    $ASLN
    $DMK
    Financials

    Live finance-specific insights

    View All

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

    – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – – Total Revenue was $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $115 Million for Full Year 2025 – – Company Provides Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Feb. 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapie

    2/12/26 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    -- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET -- NEWTON, Mass., Feb. 5, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 12, 2026, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to b

    2/5/26 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care